The naming mess around GH001 is annoying, but it is not mysterious. Think of it as a stack: mebufotenin / 5-MeO-DMT on the compound-name layer, GH001 on the company program/formulation layer, and trial results on the evidence layer.
That distinction matters because the results are worth reading on their own. In the JAMA Psychiatry paper, GH001 is described as a synthetic formulation of inhaled mebufotenin in adults with treatment-resistant depression. The paper reports a large day-8 MADRS separation and day-8 remission in 57.5% of GH001 patients versus 0 on placebo. That is the signal. The names should help you understand it, not bury it.
The names, without the fog
Mebufotenin is the compound-name language the paper uses. 5-MeO-DMT is the shorthand many readers already know. GH001 is GH Research’s clinical asset: the inhaled formulation/program being tested. So do not read GH001 as simply another synonym. Read it as the program sitting on top of that compound layer.
What each source is doing
The paper is the best anchor for the compound-to-program relationship: GH001 as inhaled mebufotenin. ClinicalTrials.gov keeps the record organized around the GH001 trial in treatment-resistant depression. GH Research’s releases connect the same package to the FDA clinical-hold lift, the JAMA publication, and the company’s planned Phase 3 path.
Those sources are compatible, but they are not written for the same job. A journal abstract, a registry record, and an investor release all compress the story differently. That is where headlines can start to flatten the stack.
The useful read
A careful reader does not need to overcomplicate this. Say GH001 when you mean the GH Research program. Say mebufotenin or 5-MeO-DMT when you are talking about the compound language. Say exactly which source carries the claim when you are talking about efficacy, safety, regulatory status, or Phase 3 plans.
The bottom line: GH001 now has a peer-reviewed phase 2b signal that deserves attention. It also still needs the discipline any pre-Phase 3 psychedelic drug story needs. The clean story is not “all the names mean the same thing.” It is: GH Research’s GH001 program is built around inhaled mebufotenin, the direct-source evidence is promising, and the next real test is whether that promise holds up in pivotal development.